Currently out of the existing stock ratings of Bradley Canino, 92 are a BUY (80%), 23 are a HOLD (20%).

Bradley Canino

Work Performance Price Targets & Ratings Chart

Analyst Bradley Canino, currently employed at STIFEL, carries an average stock price target met ratio of 35.28% that have a potential upside of 44.67% achieved within 105 days.

Bradley Canino’s has documented 226 price targets and ratings displayed on 18 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on JANX, Janux Therapeutics at 03-Dec-2024.

Wall Street Analyst Bradley Canino

Analyst best performing recommendations are on DCPH (DECIPHERA PHARMACEUTICALS LLC).
The best stock recommendation documented was for ARVN (ARVINAS) at 11/8/2023. The price target of $42 was fulfilled within 49 days with a profit of $25.49 (154.39%) receiving and performance score of 31.51.

Average potential price target upside

of $28.47 (185.27%) on ARVN (ARVINAS).
of $26.57 (45.29%) on BPMC (BLUEPRINT MEDICINES CORP).
of $21.5 (100.24%) on MRUS (MERUS BV).

ALXO Alx Oncology Holdings ARVN Arvinas BPMC Blueprint Medicines Corp CCCC C4 Therapeutics DCPH Deciphera Pharmaceuticals LLC TPTX Turning Point Therapeutics ZNTL Zentalis Pharmaceuticals Llc BDTX Black Diamond Therapeutics KYMR Kymera Therapeutics AFMD Affimed NV MRUS Merus BV RLAY Relay Therapeutics KURA Kura Oncology SNDX Syndax Pharmaceuticals THRX Theseus Pharmaceuticals NUVL Nuvalent CELC Celcuity LLC JANX Janux Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Colin Bristow (UBS)